Cargando…

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer

BACKGROUND: The role of adjuvant chemotherapy (ACT) for patients with stage IB–IIA non‐small cell lung cancer (NSCLC) according to the eighth edition of the AJCC TNM staging system remains controversial. METHODS: Data were collected from patients with NSCLC stage IB–IIA according to the eighth editi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Pei, Duan, Jianchun, Bai, Hua, Wang, Zhijie, Gao, Shugeng, Tan, Fengwei, Gao, Yushun, Wang, Xin, Wan, Rui, Xu, Jiachen, He, Xiran, Feng, Xiaoshuang, Yu, Ruofei, Sun, Jing, Zhao, Zhe, Fei, Kailun, Li, Ni, He, Jie, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779205/ https://www.ncbi.nlm.nih.gov/pubmed/33111432 http://dx.doi.org/10.1111/1759-7714.13685

Ejemplares similares

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB–IIA cervical cancer patients
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
por: Yu, Ruofei, et al.
Publicado: (2021)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Solitary fibrous tumors of the pleura: A single center experience at National Cancer Center, China
por: Tan, Fengwei, et al.
Publicado: (2018)

Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2020)

Development of a predictive nomogram for cause-specific mortality in surgically resected early-stage oesophageal cancer: a Surveillance, Epidemiology, and End Results (SEER) analysis
por: Yu, Xiangyang, et al.
Publicado: (2020)

Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
por: Tian, Yanhua, et al.
Publicado: (2022)

Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting
por: Jung, Phill-Seung, et al.
Publicado: (2015)

Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients
por: Zeng, Qingpeng, et al.
Publicado: (2021)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Effectiveness of neoadjuvant immunochemotherapy compared to neoadjuvant chemotherapy in non-small cell lung cancer patients: Real-world data of a retrospective, dual-center study
por: Fei, Kailun, et al.
Publicado: (2023)

Plasma metabolomics study in screening and differential diagnosis of multiple primary lung cancer
por: Liu, Zixu, et al.
Publicado: (2023)

Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathway
por: Yu, Ruofei, et al.
Publicado: (2020)

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
por: Sun, Sijin, et al.
Publicado: (2020)

m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma
por: Gao, Yushun, et al.
Publicado: (2016)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
por: Chen, Po-Huang, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy followed by radical surgery for FIGO stage IB2/IIA2 cervical cancer: A multi-center retrospective clinical study
por: Zhao, Hui, et al.
Publicado: (2019)

Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer
por: Huang, Yuhui, et al.
Publicado: (2022)

Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
por: Wang, Chao, et al.
Publicado: (2023)

Radical surgery for stage IB2/IIA2 cervical cancer: A large retrospective study
por: Zhou, Fang, et al.
Publicado: (2022)

Development and validation of a prognostic nomogram for 2018 FIGO stages IB1, IB2, and IIA1 cervical cancer: a large multicenter study
por: Chen, Xiaolin, et al.
Publicado: (2022)

A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma
por: Xie, Yangyang, et al.
Publicado: (2023)

Specific organ metastases and prognosis in lung adenocarcinoma
por: Zhao, Ziran, et al.
Publicado: (2023)

Prognostic significance of eighth edition TNM stage criteria in combined small-cell lung cancer
por: Zhao, Ziran, et al.
Publicado: (2023)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Uniportal versus multiportal thoracoscopic sleeve lobectomy for the surgical treatment of centrally located lung cancer: a single institution experience
por: Zhao, Jun, et al.
Publicado: (2020)

A rare case of primary pulmonary inflammatory pseudotumor-like follicular dendritic cell sarcoma successfully treated by lobectomy
por: He, Huayu, et al.
Publicado: (2021)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
por: Han, Jiefei, et al.
Publicado: (2021)

Outcome evaluation of neoadjuvant chemotherapy in patients with stage IB2 or IIA cervical cancer: a retrospective comparative study
por: Yan, Wenxing, et al.
Publicado: (2020)

Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer
por: Wu, San-Gang, et al.
Publicado: (2017)

Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
por: Matsuo, Koji, et al.
Publicado: (2017)

The Prognostic Significance Of Pretreatment Albumin/alkaline Phosphatase Ratio In Patients With Stage IB-IIA Cervical Cancer
por: Zhang, Can, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c9c4dcrqtcvh1qe1oll4tfor6r